In conclusion, our results suggest that nuclear expression of PHF2 and C/EBPα may serve as a prognostic marker and that the oncogenic metabolic shift has progressed in ccRCC patients. This evidence concerns the gene PHF2 and nonpapillary renal cell carcinoma.